about
Large-scale long-term follow-up study of Japanese patients with non-alcoholic Fatty liver disease for the onset of hepatocellular carcinoma.Outcome of All-Oral Direct-Acting Antiviral Regimens on the Rate of Development of Hepatocellular Carcinoma in Patients with Hepatitis C Virus Genotype 1-Related Chronic Liver Disease.Virologic breakthrough in a patient with chronic hepatitis B by combination treatment with tenofovir disoproxil fumarate and entecavir.Highly sensitive AFP-L3% assay is useful for predicting recurrence of hepatocellular carcinoma after curative treatment pre- and postoperatively.Prevalence of hepatitis C virus variants resistant to NS3 protease inhibitors or the NS5A inhibitor (BMS-790052) in hepatitis patients with genotype 1b.New discriminant score to predict the fibrotic stage of non-alcoholic steatohepatitis in JapanImpact of Mutations at Amino Acid 70 in Hepatitis C Virus (HCV) Genotype 1b Core Region on Hepatocarcinogenesis following Eradication of HCV RNA.Analysis of association between circulating miR-122 and histopathological features of nonalcoholic fatty liver disease in patients free of hepatocellular carcinoma.Long-term effects of peginterferon alfa-2a therapy in Japanese patients with chronic hepatitis B virus infection.Transcatheter arterial chemotherapy with miriplatin for hepatocellular carcinoma patients with chronic renal failure: report of three cases.Relationships between Genetic Variations of PNPLA3, TM6SF2 and Histological Features of Nonalcoholic Fatty Liver Disease in JapanPrediction of treatment efficacy and telaprevir-resistant variants after triple therapy in patients infected with hepatitis C virus genotype 1.What Is the Most Effective Drug Delivery System for Cisplatin during the Treatment of Hepatic Tumors with Single-Session Transcatheter Chemotherapy? A Pilot Study.Utility of detection of telaprevir-resistant variants for prediction of efficacy of treatment of hepatitis C virus genotype 1 infection.New Discriminant Method for Identifying the Aggressive Disease Phenotype of Non-alcoholic Fatty Liver Disease.Clinical features of hepatitis B virus genotype A in Japanese patients.Sustained virologic response by direct antiviral agents reduces the incidence of hepatocellular carcinoma in patients with HCV infection.Serial changes in liver stiffness and controlled attenuation parameter following direct-acting antiviral therapy against hepatitis C virus genotype 1b.Direct-Acting Antivirals Decreased Tumor Recurrence After Initial Treatment of Hepatitis C Virus-Related Hepatocellular Carcinoma.Prognosis and predictors of hepatocellular carcinoma in elderly patients infected with hepatitis B virus.Diabetes mellitus increases the risk of hepatocarcinogenesis in patients with alcoholic cirrhosis: A preliminary report.Long-term outcome of HBV carriers with negative HBe antigen and normal aminotransferase.Predictors of pruritus in patients with chronic liver disease and usefulness of nalfurafine hydrochloride.Transcatheter arterial chemotherapy using miriplatin-lipiodol suspension with or without embolization for unresectable hepatocellular carcinoma.The efficacy and safety of dual oral therapy with daclatasvir and asunaprevir for genotype 1b in Japanese real-life settings.Ledipasvir plus sofosbuvir as salvage therapy for HCV genotype 1 failures to prior NS5A inhibitors regimens.Favorable efficacy of daclatasvir plus asunaprevir in treatment of elderly Japanese patients infected with HCV genotype 1b aged 70 and older.Efficacy of long-term tenofovir-based rescue therapy in patients with chronic hepatitis B refractory to nucleoside/nucleotide analogs.Usefulness of serum KL-6 for early diagnosis of idiopathic pulmonary fibrosis in patients with hepatitis C virus.Liver Fibrosis and Body Mass Index Predict Hepatocarcinogenesis following Eradication of Hepatitis C Virus RNA by Direct-Acting Antivirals.The influence of hepatitis B virus genotype on the development of lamivudine resistance during long-term treatment.Retreatment efficacy and predictors of ledipasvir plus sofosbuvir to HCV genotype 1 in Japan.Three-dimensional magnetic resonance imaging for stringent diagnosis of advanced fibrosis associated with nonalcoholic steatohepatitis.Long-Term Outcomes of Hepatitis-C-Infected Patients Achieving a Sustained Virological Response and Undergoing Radical Treatment for Hepatocellular Carcinoma.Impact of circulating miR-122 for histological features and hepatocellular carcinoma of nonalcoholic fatty liver disease in Japan.Relationships between serum asunaprevir concentration and alanine aminotransferase elevation during daclatasvir plus asunaprevir for chronic HCV genotype 1b infection.Evolution of simeprevir-resistant variants in virological non-responders infected with HCV genotype 1b.Long-term entecavir therapy results in falls in serum hepatitis B surface antigen levels and seroclearance in nucleos(t)ide-naïve chronic hepatitis B patients.Cholangiolocellular Carcinoma in a Young Patient Who Showed Sustained Virological Response after Treatment for Hepatitis C Virus Infection.Factors associated with the effect of interferon-α sequential therapy in order to discontinue nucleoside/nucleotide analog treatment in patients with chronic hepatitis B.
P50
Q33397694-F5B44E96-06A0-4561-A256-DA7B99BFD0FAQ33441426-55AB02D0-A7E2-4CBE-9E58-3027C1F4ADA9Q33857643-9ECC60E1-ADB3-4703-A89C-B7352599591FQ34631965-87A738B5-2257-46AD-817A-D25B9AF22402Q34638767-314C50EE-3EC5-4327-B07E-99EE4064712AQ35289022-4A37A053-C1FD-4628-A09B-033ACA714028Q35968616-C79C9D31-4B80-4317-93E7-CB67529B3E24Q36220756-32A30369-4284-4F2C-91DE-9C3DB239451DQ36401963-33EC7377-AF46-41AC-BAFA-672737E05EA9Q36715169-E38D26F8-FD08-46D5-B01C-C445612CE023Q36848963-5ED2DBC8-5B0A-4903-B8AE-A84FE5487C76Q37125066-6DD15269-E8AE-428C-8B48-9EBCFAF23D7DQ37196482-07765651-7659-4EA3-8CB5-BEFD1119A702Q37546699-99AB4DBE-3337-42F4-A498-66BC33BB6540Q38720197-DC345798-B226-4DBF-81FD-4C731FEE9A39Q39142527-4F712A96-FD80-46F6-B58B-D49908D96A78Q39483711-ECC63EC8-6C9D-484D-84CF-A4B377C2DD82Q40041670-354AC279-FFBF-4784-A175-10DD63240BC7Q40051671-58B10A0F-B092-45A2-B28D-B346FBE7CFCEQ40138677-A3C342B1-7DEF-492F-9925-39AC7ED18BF7Q40207862-6814DEB5-4B7B-4979-8900-A53FE73DE50FQ40274896-A32AB341-06F9-49B0-A92C-DD035B7B6636Q40283352-389560FD-F4EF-4F2C-8CF8-5D6E20D2DD93Q40300538-E6C87926-4E7D-4AC5-AC30-658CDAC3C9B7Q40340001-024A1038-89D8-42D7-9436-C1A36F6342BBQ40375140-E28547A2-5B05-4D4E-A9A6-9C62BBD35362Q40473920-37F5EED9-D2BD-4034-9FC4-A138D3CC94A3Q40555175-B9DA017F-72C2-4A6C-94D4-AB99031015B8Q40555460-C0590E66-3E97-4B6C-94E5-FC3C0CEB4953Q40557264-30CABB81-31CE-4B43-A62B-053E61FBB58CQ40605234-1D3B6216-AE10-4ED0-BCB5-83A220AA7C3FQ40631323-59E0F31B-4E51-42A0-86C1-F42043ADC33DQ40706953-42C798B3-DAA6-43AB-B10C-CCFE5953F990Q40782607-9791C13F-9C3E-4475-A7DA-2E4C6927B64CQ40802631-B40EB4C5-6B02-4C94-B107-912BD9F0AB3BQ41041935-ED3D0FE1-AB13-4980-8195-A5D64C9D0AF8Q41473188-67240CC2-C3A0-4E7C-ACB6-3CC67B6D4313Q41719578-811A965F-9E38-4192-8185-160E9CC3922AQ41931003-1CE5A26E-A2E9-45FE-8116-BFA44F50D2BEQ42174830-C2D9D83F-AF8F-402C-A53C-4241E664BBDE
P50
description
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Tetsuya Hosaka
@ast
Tetsuya Hosaka
@en
Tetsuya Hosaka
@es
Tetsuya Hosaka
@nl
Tetsuya Hosaka
@sl
type
label
Tetsuya Hosaka
@ast
Tetsuya Hosaka
@en
Tetsuya Hosaka
@es
Tetsuya Hosaka
@nl
Tetsuya Hosaka
@sl
prefLabel
Tetsuya Hosaka
@ast
Tetsuya Hosaka
@en
Tetsuya Hosaka
@es
Tetsuya Hosaka
@nl
Tetsuya Hosaka
@sl
P106
P1153
7102020634
P31
P496
0000-0003-0302-2275